Iguana Healthcare Management LLC boosted its position in shares of Merck & Company, Inc. (NYSE:MRK) by 13.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 125,000 shares of the company’s stock after purchasing an additional 15,000 shares during the quarter. Merck & accounts for about 3.9% of Iguana Healthcare Management LLC’s investment portfolio, making the stock its 6th biggest holding. Iguana Healthcare Management LLC’s holdings in Merck & were worth $7,943,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of MRK. GW&K Investment Management LLC boosted its holdings in shares of Merck & by 4.7% in the first quarter. GW&K Investment Management LLC now owns 408,948 shares of the company’s stock valued at $25,985,000 after buying an additional 18,340 shares during the period. Gulf International Bank UK Ltd boosted its holdings in shares of Merck & by 1.9% in the first quarter. Gulf International Bank UK Ltd now owns 861,540 shares of the company’s stock valued at $54,742,000 after buying an additional 15,700 shares during the period. Augustine Asset Management Inc. boosted its holdings in shares of Merck & by 1.8% in the first quarter. Augustine Asset Management Inc. now owns 85,615 shares of the company’s stock valued at $5,439,000 after buying an additional 1,529 shares during the period. Dynamic Advisors Solutions LLC boosted its holdings in shares of Merck & by 11.2% in the first quarter. Dynamic Advisors Solutions LLC now owns 8,852 shares of the company’s stock valued at $562,000 after buying an additional 894 shares during the period. Finally, Lynch & Associates IN boosted its holdings in shares of Merck & by 4.9% in the first quarter. Lynch & Associates IN now owns 86,323 shares of the company’s stock valued at $5,485,000 after buying an additional 4,042 shares during the period. Hedge funds and other institutional investors own 72.91% of the company’s stock.
Several research firms have issued reports on MRK. BMO Capital Markets reaffirmed an “outperform” rating and set a $73.00 price target (down from $74.00) on shares of Merck & in a research report on Monday, July 24th. BidaskClub lowered shares of Merck & from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Citigroup Inc. set a $65.00 price objective on shares of Merck & and gave the company a “hold” rating in a report on Wednesday, July 5th. HSBC Holdings plc upgraded shares of Merck & from a “reduce” rating to a “hold” rating in a report on Wednesday, August 9th. Finally, Zacks Investment Research downgraded shares of Merck & from a “buy” rating to a “hold” rating in a report on Monday, June 12th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $70.00.
TRADEMARK VIOLATION WARNING: “Iguana Healthcare Management LLC Has $7.94 Million Position in Merck & Company, Inc. (MRK)” was originally published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.truebluetribune.com/2017/09/25/merck-company-inc-mrk-is-iguana-healthcare-management-llcs-6th-largest-position.html.
Merck & Company, Inc. (NYSE MRK) opened at 65.13 on Monday. Merck & Company, Inc. has a one year low of $58.29 and a one year high of $66.80. The company has a market cap of $177.63 billion, a price-to-earnings ratio of 35.26 and a beta of 0.81. The company has a 50-day moving average of $63.52 and a 200-day moving average of $63.68.
Merck & (NYSE:MRK) last posted its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.14. The business had revenue of $9.93 billion for the quarter, compared to the consensus estimate of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.93 EPS. Equities research analysts expect that Merck & Company, Inc. will post $3.87 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 6th. Stockholders of record on Friday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Thursday, September 14th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.89%. Merck &’s payout ratio is 76.11%.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.